SARS-CoV-2 adaptive immunity in nursing home residents up to eight months after two doses of the Comirnaty® COVID-19 vaccine - 20/05/22

Doi : 10.1016/j.jinf.2022.02.035

Estela Giménez ^a, Eliseo Albert ^a, Javier S. Burgos ^b, Salvador Peiró ^c, Dolores Salas ^c,^d, Hermelinda Vanaclocha ^d, Ramón Limón ^e, María Jesús Alcaraz ^a, José Sánchez-Payá ^f,^g, Javier Díez-Domingo ^c, Iñaki Comas ^h, Fernando Gonzáles-Candelas ⁱ
on behalf of the
Valencian vaccine research program (ProVaVac) study group^a,^j,^⁎,^{^†}
Members of the Valencian vaccine research program (ProVaVac) study group:
^a Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain
^b General Directorate of Research and Healthcare Supervision, Department of Health, Valencia Government, Valencia, Spain
^c Foundation for the promotion of health and biomedical research of the Valencian Community (FISABIO), Valencia, Spain
^d General Directorate of Public Health, Department of Health, Valencia Government, Valencia, Spain
^e General Directorate of Healthcare. Department of Health, Valencian Government, Valencia, Spain
^f Preventive Medicine Service, Alicante General and University Hospital, Alicante, Spain
^g Alicante Institute of Health and Biomedical Research (ISABIAL), Alicante, Spain
^h Biomedicine Institute of Valencia, Spanish Research Council (CSIC)
ⁱ CIBER in Epidemiology and Public Health, Spain, Joint Research Unit "Infection and Public Health" FISABIO-University of Valencia, Valencia, Spain; Institute for Integrative Systems Biology (I2SysBio), CSIC-University of Valencia, Valencia, Spain
^j Department of Microbiology, School of Medicine, University of Valencia, Valencia, Spain

^⁎Corresponding author at: Microbiology Service, Hospital Clínico Universitario, Instituto de Investigación INCLIVA. Av. Blasco Ibáñez 17, 46010 Valencia, Spain.Microbiology ServiceHospital Clínico UniversitarioInstituto de Investigación INCLIVA. Av. Blasco Ibáñez 17Valencia46010Spain

connectez-vous ou créez un compte

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

Abstract

Burgos JS (General Directorate of Research and Healthcare Supervision, Department of Health, Valencia Government, Valencia, Spain); Meneu de Guillerna R (Vice-President Foundation Research Institute in Public Services, Valencia, Spain); Vanaclocha Luna H (General Directorate of Public Health, Department of Health, Valencia Government, Valencia, Spain); Burks DJ (The Prince Felipe Research Center-CIPF-, Valencia, Spain; Cervantes A (INCLIVA Health Research Institute, Valencia, Spain); Comas I (Biomedicine Institute of Valencia, Spanish Research Council (CSIC); Díez-Domingo J (Foundation for the promotion of health and biomedical research of the Valencian Community-FISABIO-, Valencia, Spain); Peiro S (Foundation for the promotion of health and biomedical research of the Valencian Community-FISABIO-, Valencia, Spain); González-Candelas F (CIBER in Epidemiology and Public Health, Spain; Joint Research Unit "Infection and Public Health" FISABIO-University of Valencia, Valencia, Spain; Institute for Integrative Systems Biology (I2SysBio), CSIC-University of Valencia, Valencia, Spain); Ferrer Albiach C (Fundación Hospital Provincial de Castelló); Hernández-Aguado I (University Miguel Hernández, Alicante, Spain); Oliver Ramírez N (DataPop Alliance); Sánchez-Payá J (Preventive Medicine Service, Alicante General and University Hospital, Alicante, Spain; Alicante Institute of Health and Biomedical Research (ISABIAL), Alicante, Spain; Vento Torres M (Instituto de Investigación Sanitaria La Fe); Zapater Latorre E (Fundación Hospital General Universitario de València); Navarro D (Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain;Department of Microbiology, School of Medicine, University of Valencia, Valencia, Spain).

Le texte complet de cet article est disponible en PDF.

Keywords : SARS-CoV-2, Comirnaty^® COVID-19 vaccine, SARS-CoV-2-S antibodies, SARS-CoV-2-S T cells, nursing home residents

Plan

FINANCIAL SUPPORT

CONFLICTS of INTEREST

AUTHOR CONTRIBUTIONS

Export

Vol 84 - N° 6

P. 834-872 - juin 2022 Retour au numéro

Article précédent

Wild poliovirus outbreak in Afghanistan: A wake-up call for global health experts
Usman Ayub Awan, Muhammad Wasif Malik, Shehrish Kamran, Haroon Ahmed, Mohsina Haq, Muhammad Sohail Afzal

| Article suivant

Vaccine Ab neutralization against Omicron and SARS-CoV-2 variants using neutralization and specific ELISA assays
Valentine Marie Ferré, Samuel Lebourgeois, Houssem Redha Chenane, Reyene Menidjel, Christelle Masson, Gilles Collin, Benoit Visseaux, Diane Descamps, Nadhira Fidouh, Charlotte Charpentier

Bienvenue sur EM-consulte, la référence des professionnels de santé.

connectez-vous ou créez un compte

SARS-CoV-2 adaptive immunity in nursing home residents up to eight months after two doses of the Comirnaty® COVID-19 vaccine - 20/05/22

Abstract

Plan

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL